CLINICAL TRIALS PROFILE FOR IBRITUMOMAB TIUXETAN

All Clinical Trials for ibritumomab tiuxetan

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00017381 ↗	Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	Completed	National Cancer Institute (NCI)	Early Phase 1	2001-04-01	This phase I trial is studying how well monoclonal antibody therapy with peripheral stem cell transplant works in treating patients with non-Hodgkin's lymphoma. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Peripheral stem cell transplant may allow the doctor to give higher doses of monoclonal antibodies and kill more cancer cells
NCT00038623 ↗	Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma	Completed	Biogen	Phase 2	2002-04-01	Study of Yttrium-ibritumomab (Zevalin) For the treatment of Patients with Relapsed & Refractory Mantle Cell Lymphoma
NCT00038623 ↗	Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	2002-04-01	Study of Yttrium-ibritumomab (Zevalin) For the treatment of Patients with Relapsed & Refractory Mantle Cell Lymphoma
NCT00058292 ↗	Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Completed	National Cancer Institute (NCI)	Phase 1	2000-04-01	RATIONALE: Radiolabeled monoclonal antibodies such as yttrium Y90 ibritumomab tiuxetan can locate cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining yttrium Y90 ibritumomab tiuxetan and chemotherapy with autologous stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase I trial is studying how well giving yttrium Y90 ibritumomab tiuxetan with high-dose chemotherapy followed by autologous stem cell transplant work in treating patients with relapsed or refractory non-Hodgkin's lymphoma.

Clinical Trial Conditions for ibritumomab tiuxetan

Condition Name

Condition Name for ibritumomab tiuxetan
Intervention	Trials
Lymphoma	23
Non-Hodgkin's Lymphoma	7
Diffuse Large B-Cell Lymphoma	6
Recurrent Adult Diffuse Large Cell Lymphoma	5

Condition MeSH

Condition MeSH for ibritumomab tiuxetan
Intervention	Trials
Lymphoma	72
Lymphoma, Non-Hodgkin	32
Lymphoma, B-Cell	24
Lymphoma, Large B-Cell, Diffuse	17

Clinical Trial Locations for ibritumomab tiuxetan

Trials by Country

Trials by Country for ibritumomab tiuxetan
Location	Trials
United States	176
Italy	42
Spain	18
France	9
Canada	8

Trials by US State

Trials by US State for ibritumomab tiuxetan
Location	Trials
California	12
Illinois	11
Texas	11
Massachusetts	8
New York	8

Clinical Trial Progress for ibritumomab tiuxetan

Clinical Trial Phase

Clinical Trial Phase for ibritumomab tiuxetan
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	8
Phase 2	49

Clinical Trial Status

Clinical Trial Status for ibritumomab tiuxetan
Clinical Trial Phase	Trials
Completed	43
Terminated	14
Unknown status	8

Clinical Trial Sponsors for ibritumomab tiuxetan

Sponsor Name

Sponsor Name for ibritumomab tiuxetan
Sponsor	Trials
National Cancer Institute (NCI)	19
Bayer	9
Biogen	9

Sponsor Type

Sponsor Type for ibritumomab tiuxetan
Sponsor	Trials
Other	84
Industry	33
NIH	20

Ibritumomab Tiuxetan: Clinical Trials, Market Analysis, and Future Projections

Last updated: February 9, 2026

---

What Is the Current Status of Clinical Development for Ibritumomab Tiuxetan?

Ibritumomab tiuxetan (Zevalin) remains an approved radioimmunotherapy, primarily used for relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). Its clinical use is well-established, but ongoing trials aim to evaluate its efficacy in broader indications and combination therapies.

Existing Approvals and Indications

• FDA approval (2002): Treatment of follicular lymphoma (FL) in patients with relapsed or refractory disease after at least two prior therapies.
• EMA approval: Similar indications, with some regional variations.

Active Clinical Trials

As of 2023, the United States ClinicalTrials.gov registry lists eight active or ongoing studies involving ibritumomab tiuxetan. The focus centers on:

• Combining with other agents such as rituximab, bendamustine, and checkpoint inhibitors to improve efficacy.
• Testing in first-line settings for specific subpopulations.
• Evaluating in marginal zone lymphoma, Waldenström’s macroglobulinemia, and other indolent lymphomas.

Notable Trials

Trial ID	Title	Phase	Focus	Estimated Completion
NCT04552391	Ibritumomab in combination with pembrolizumab	Phase 2	Relapsed indolent NHL	2024
NCT04391069	Ibritumomab + bendamustine	Phase 3	First-line follicular lymphoma	2025

Most trials are in Phase 1 or 2, indicating development is directed toward expanding indications and optimizing therapeutic regimens.

---

How Does Ibritumomab Tiuxetan Perform in the Market?

Market Size and Trends

The global radioimmunotherapy market was valued at approximately $292 million in 2022. Ibritumomab tiuxetan accounted for an estimated 35% of this segment.

Competitive Landscape

Product	Approval Year	Indications	Market Share (Estimate)	Key Competitors
Zevalin	2002	CD20-positive NHL	35%	Rituximab, Obinutuzumab, CAR T-cell therapies
Bexxar (not marketed)	2003	NHL	Ceased market	-

Bexxar, a comparable radioimmunotherapy, was withdrawn from the market due to strategic decisions, leaving Zevalin with limited competition in its niche.

Distribution and Adoption

• The U.S. maintains the largest market share.
• Use is limited by factors including the need for specialized administration, radioprotection measures, and reimbursement challenges.
• Some European countries show cautious adoption, partly due to regulatory hurdles and preference for non-radioactive monoclonal antibodies.

---

What Are the Future Market Projections for Ibritumomab Tiuxetan?

Growth Drivers

• Expansion of indications: Trials targeting first-line treatment, combination therapies, and other NHL subtypes could lead to broader acceptance.
• Advances in immunotherapy: Combination approaches with checkpoint inhibitors and CAR T-cell therapies are anticipated to increase demand.
• Regulatory approvals: Potential approvals in additional countries or for new indications would buoy market prospects.

Forecasts (2023-2030)

• The market is projected to grow at a compound annual growth rate (CAGR) of approximately 5.8%, reaching an estimated $400 million by 2030.
• Growth will be tempered by competition from emerging therapies and the limited number of indications currently approved for radioimmunotherapy.

Risks and Challenges

• Regulatory approval delays for new indications.
• Reimbursement issues stemming from high treatment costs.
• Rising competition from non-radioactive monoclonal antibodies and newer immunotherapies.

---

Key Takeaways

• Clinical development for ibritumomab tiuxetan focuses on expanding its use in various NHL subtypes and combination regimens.
• The drug retained a significant market share in radioimmunotherapy but faces competitive pressure from novel treatments.
• Market growth prospects depend on successful expansion into new indications, regulatory approvals, and integration with combination therapies.
• Challenges include high treatment costs, regulatory complexities, and competition from non-radioactive therapies.
• By 2030, the radioimmunotherapy segment, led by agents like ibritumomab tiuxetan, could see moderate growth, driven by clinical trial successes and evolving treatment paradigms.

---

FAQs

1. What are the main limitations of ibritumomab tiuxetan?
The need for specialized handling due to radioactivity, potential myelosuppression, and limited indications restrict widespread adoption.

2. Is ibritumomab tiuxetan approved outside the US and Europe?
Approval and availability vary; some countries lack regulatory approval or have limited access due to logistical and safety concerns.

3. Are there ongoing efforts to develop alternative radiolabeled antibodies?
Yes. New agents with improved targeting, shorter half-lives, and better safety profiles are under investigation, potentially replacing or complementing existing therapies.

4. How does the efficacy of ibritumomab tiuxetan compare with non-radioactive anti-CD20 antibodies?
Clinical trials suggest comparable efficacy in relapsed settings, but non-radioactive antibodies often have fewer logistical challenges and broader usage.

5. What is the outlook for combination therapies involving ibritumomab tiuxetan?
Such combinations aim to improve response rates, especially in refractory cases, with promising early-phase trial results, enhancing future market potential.

---

Sources

[1] ClinicalTrials.gov, 2023. Search results for ibritumomab tiuxetan.
[2] Grand View Research, 2023. Radioimmunotherapy market report.
[3] U.S. FDA. Zevalin (ibritumomab tiuxetan) label.
[4] European Medicines Agency. Zevalin approval documents.